Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Health Economics and Policy, Basic & Translational Research

The Economics of Gene Therapy

At a Glance

  • As they advance through clinical trials, gene therapies are coming closer and closer to reality for patients with retinal diseases
  • But with approaching treatments come approaching costs, and gene therapies can cost as much as US$1 million for a single treatment
  • Especially in disorders with small patient populations, like many ocular diseases, the price per dose of a new therapy must be high – which can prevent patients from accessing it
  • I propose a model of annuity payments for gene and stem cell therapies that would charge based on both the duration of treatment and the degree of efficacy

Gene therapy looks like it will transform the treatment of a number of ophthalmic diseases in the near future. Clinical trials in a number of retinal diseases, including Leber congenital amaurosis (LCA), the wet form of AMD, Stargardt disease/ Stargardt’s macular dystrophy (SMD), and Usher Syndrome 1b have shown promising results, with gene therapy providing some vision improvement for most who received it, without causing significant safety concerns. Of course, some questions about gene therapy still remain – will it deliver Ricki Lewis’ holy grail of “the forever fix” (1), or something less? And, with the first Western world approval of a gene therapy treatment – Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency (LPLD) – having been gained, will ophthalmic therapies be next?

But these aren’t the only questions being asked. As ophthalmic gene therapy approaches marketing approval, likely within the next 2–3 years, one of the most significant concerns is cost. Glybera treatment may cost as much as $1.6 million per patient (2) but the extent of its worldwide market numbers in the hundreds – this is whole orders of magnitude smaller than the potential market size of the ophthalmic diseases currently under investigation. Nobody expects any of the proposed ophthalmic treatments to cost that much, as most of the disorders to be treated have much larger patient populations, but that unanswered question remains. What will ocular gene therapy (and, perhaps, stem cell treatment) cost? And how will patients and the medical community pay for it?

Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login as a Guest or via Social Media

About the Author

Irv Arons

Irv Arons

Irv Arons’ Journal&nbsp; (<a class="external-link-new-window" title="Opens external link in new window" href="http://irvaronsjournal.blogspot.com/">http://irvaronsjournal.blogspot.com</a>/) is a well-read blog that reports on new drugs and devices for the treatment of retinal diseases, including age-related macular degeneration (AMD). Until his retirement, Irv was a consultant to the ophthalmic and medical laser industries, working for management consultants Arthur D. Little for 25 years and running his own company, Spectrum Consulting, for 11 years.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register